People: Cytori Therapeutics, Inc. (CYTX.O)

CYTX.O on Consolidated Issue listed on NASDAQ Global Market

6.82USD
10:24am EST
Price Change (% chg)

$-0.02 (-0.29%)
Prev Close
$6.84
Open
$6.84
Day's High
$6.90
Day's Low
$6.78
Volume
86,720
Avg. Vol
1,135,919
52-wk High
$9.50
52-wk Low
$1.42

view people for:

Summary

Name Age Since Current Position
Henriksen, Ronald 70 2007 Chairman of the Board
Calhoun, Christopher 43 2004 Chief Executive Officer, Director
Hedrick, Marc 46 2004 President, Director
Saad, Mark 39 2004 Chief Financial Officer
Shirahama, Seijiro 55 2007 President - Asia Pacific
Reuter, Bruce 60 2006 Senior Vice President - International Sales, Marketing & Distribution
Arm, Douglas 40 2009 Senior Vice President - Operations
Milstein, Alexander 49 2005 Vice President - Clinical Development
Kleinhenz, Kenneth 45 2007 Vice President - Quality & Regulatory Affairs
Rickey, David 53 1999 Director
Holmes, E. Carmack 71 2003 Director
Hawran, Paul 57 2005 Director
Hawkins, Richard 60 2007 Director
» Insider Trading

Biographies

Name Description
Henriksen, Ronald Mr. Ronald D. Henriksen is Chairman of the Board of Cytori Therapeutics Inc. He joined as a Director in October 2002 and was appointed Chairman of the Board in April 2007. Mr. Henriksen was previously a board member of predecessor, StemSource, Inc., and has more than 30 years of experience in healthcare, pharmaceutical, biotechnology and consulting and venture capital industries. He currently serves as Chief Investment Officer of Twilight Ventures, LLC, Chairman of the Board of Angel Learning, Inc., and President and board member of EndGenitor Technologies, Inc. In addition, he is on the Board of Directors of Semafore Pharmaceuticals and Biostorage Technologies, Inc. For more than 20 years, Mr. Henriksen held executive positions with Eli Lilly, where he served as Managing Director for Brazil, Mexico and Central America, and negotiated international contracts through Lilly Business Development. He earned a B.S. in Industrial Administration at Iowa State University and an M.B.A. with distinction from Harvard Business School. Mr. Henriksen also served as an officer for four years in the U.S. Navy.
Calhoun, Christopher Mr. Christopher J. Calhoun is Chief Executive Officer and Director of Board of Cytori Therapeutics Inc since 1997. Mr. Calhoun also served as President from April 2002 to May 2004 and from 1996 to 1998. Mr. Calhoun is a co-inventor on multiple US and International patents used for our bioresorbable implant technology. These inventions include bioresorbable polymers for skeletal repair and regeneration, implant surfaces for tissue guidance, and postsurgical scar tissue reduction. Mr. Calhoun received a BA from the University of California, San Diego and an MBA from the University of Phoenix.
Hedrick, Marc Mr. Marc H. Hedrick, M.D. is President, Director of Cytori Therapeutics Inc. He is appointed President of the Company in May 2004, and joined as Chief Scientific Officer, Medical Director and Director in October 2002. In December 2000, Dr. Hedrick co-founded and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. He is a plastic surgeon, and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick earned his M.D. degree from University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.
Saad, Mark Mr. Mark E. Saad is Chief Financial Officer of Cytori Therapeutics Inc since June 2004. Previously, Mr. Saad served as Chief Operating Officer of UBS, Healthcare Investment Banking, New York, where he was responsible for global investment banking operations. Upon joining UBS in 1999, Mr. Saad served as Director / Executive Director covering life sciences sectors - biotechnology and medical devices. Prior to joining UBS, Mr. Saad held the position of Financial Analyst/Associate with Salomon, Smith Barney, Healthcare Investment Banking, New York, where he managed public and private transactions. Mr. Saad holds a B.A. from Villanova University, Philadelphia, PA.
Shirahama, Seijiro Mr. Seijiro N. Shirahama is President – Asia Pacific in November 2007. He had served as Senior Vice President – Asia Pacific since November 2006, and as Vice President – Asia Pacific, from September 2002 to November 2006. Prior to that, from May 1999 to August 2002, he was President of Touchmetrics K.K., a diagnostic ultrasound firm. He held executive positions with Bristol-Myers Squibb K.K. from April 1997 to October 1998, and from March 1995 until March 1997, was the General Manager for Baxter Biotech Group in Tokyo, Japan. Mr. Shirahama holds a B.A. from Kanagawa University in Yokohama, Japan and an M.A. from the University of San Francisco.
Reuter, Bruce Mr. Bruce A. Reuter is Senior Vice President – International Sales, Marketing & Distribution of Cytori Therapeutics Inc since November 2006. He had served as Senior Vice President of Business Development from January 2004 to July 2006 and as Senior Vice President International Business from September 2002 to January 2004. From September 2001 to September 2002 he served as Vice President and General Manager of Bone Fixation Products, and from January 2001 to September 2001, he served as Vice President - Market Development. Before joining , from January 1990 to October 2000, Mr. Reuter served as the Vice President and Managing Director of Mentor Corporation, a multi-national marketer of medical devices. He holds a B.A. from the University of Rhode Island and an M.B.A. from Memphis State University (now known as University of Memphis).
Arm, Douglas Mr. Douglas Arm, PhD is Sr. Vice President, Operations of Cytori Therapeutics Inc since April 2009, and previously served as Vice President of Development – Regenerative Cell Technology since February 2005. Prior to joining , Dr. Arm spent more than eight years at Interpore Cross International, the last several years as Director of Biologics Research. Before joining Interpore, he completed a post-doctoral fellowship with Dr. Arnold Caplan at the Skeletal Research Center at Case Western Reserve University, examining various aspects of mesenchymal stem cells. Dr. Arm earned his B.S. in Biomedical Engineering from Johns Hopkins University in 1990, followed by his Ph.D. in Bioengineering from the University of Washington in 1995.
Milstein, Alexander Mr. Alexander M. Milstein, MD is Vice President - Clinical Development of Cytori Therapeutics Inc since June 2005. Before joining , Dr. Milstein held the position of Director of Clinical Research at Medtronic, Inc., and as Director of Clinical Research and Development from November 2004 through May 2005. From 2000 to 2003, he was employed by Guidant Corporation as Manager, Clinical Trials, where he developed and managed implementation of worldwide clinical development strategies for several device/drug combination cardiovascular products. Before joining Guidant, he was Manager of Clinical Operations at Acusphere, Inc., a specialty pharmaceutical company. Dr. Milstein earned his M.D. degree from Moscow Medical Institute No. 2 (Pirogov) in Moscow, Russia.
Kleinhenz, Kenneth Mr. Kenneth K. Kleinhenz is Vice President of Quality & Regulatory Affairs of Cytori Therapeutics Inc since November 2007. He had served as Director of Regulatory Affairs since joining in 1999. From September 1998 to June 1999, Mr. Kleinhenz was the Technical Director for IFM Manufacturing. He served as Chief Microbiologist for Becton Dickenson from June 1997 to September 1998, and as Manager of Quality Assurance and Regulatory Affairs at Pacific Pharmaceuticals from September 1993 to June 1997. Mr. Kleinhenz is a veteran of the United States Navy, where he served as a Clinical Microbiologist for six years at the Naval Hospital, San Diego. He earned his B.S. in Microbiology at the University of California, San Diego (UCSD) and his M.B.A. in Technology Management at the University of Phoenix.
Rickey, David Mr. David M. Rickey is Director of Cytori Therapeutics Inc since November 1999. Mr. Rickey has been a principal of Rickey Enterprises, a family investment firm, since 2005. From 1996 to 2005, Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation, which provides high-performance, high-bandwidth silicon solutions for optical networks. Mr. Rickey also served as a Director and Chairman of the Board of Applied Micro Circuits Corporation and as a Director of AMI Semiconductor, Inc., and he currently serves as a Director of Netlist, Inc., which designs and builds memory and application-specific modules for Internet infrastructure. He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.
Holmes, E. Carmack Mr. E. Carmack Holmes, M.D. is Director of Cytori Therapeutics Inc since August 2003. Since 1997, Dr. Holmes has served as the Executive Director of the Center for Advanced Surgery and Interventional Technology at the University of California Los Angeles (UCLA) School of Medicine. From 1995 to 2004, Dr. Holmes held the position of William P. Longmire, Jr. Professor and Chairman, Department of Surgery, UCLA School of Medicine, and from 1994 to 2004 he served as the Surgeon-in-Chief and Chairman, Department of Surgery at the UCLA Medical Center. He joined UCLA in 1973 and has held professorial positions in the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years. His surgical training was conducted at Johns Hopkins University and the National Cancer Institute at the National Institutes of Health (NIH). Dr. Holmes graduated from Duke University and holds an M.D. from the University of North Carolina Medical School.
Hawran, Paul Mr. Paul W. Hawran is Director of Cytori Therapeutics Inc since February 2005. Mr. Hawran has been Chief Financial Officer of Sequenom, Inc., a genetics company, since April 2007. In addition, he served on the Board of Directors of Sequenom from August 2006 to February 2007. Mr. Hawran served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. from January 2001 through September 2006, and as a Senior Advisor to Neurocrine from September 2006 through April 2007. Before that, he served as Senior Vice President and Chief Financial Officer of Neurocrine from 1996 to 2001 and Vice President and Chief Financial Officer from 1993 to 1996. Mr. Hawran was employed by SmithKline Beecham (now Glaxo SmithKline) from July 1984 to May 1993, most recently as Vice President and Treasurer. Prior to joining SmithKline in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John's University and an M.S. in taxation from Seton Hall University. He is a Certified Public Accountant and is a member of the American Institute of Certified Public Accountants.
Hawkins, Richard Mr. Richard J. Hawkins is Director of Cytori Therapeutics Inc since December 2007. Since 2004, he has served as the Chairman and CEO of LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company, where he served as Chairman, President, and Chief Executive Officer. In addition, he was a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. In addition to his role as Chairman of the Board for LabNow Inc., Mr. Hawkins also currently serves on the Board of Directors of Synarc, Inc. and SciClone Pharmaceuticals Inc. Mr. Hawkins holds a B.S. in biology from Ohio University.

Basic Compensation

Name Fiscal Year Total
Henriksen, Ronald --
Calhoun, Christopher 691,172
Hedrick, Marc 682,108
Saad, Mark 531,693
Shirahama, Seijiro 421,854
Reuter, Bruce 451,731
Arm, Douglas --
Milstein, Alexander --
Kleinhenz, Kenneth --
Rickey, David --
Holmes, E. Carmack --
Hawran, Paul --
Hawkins, Richard --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Henriksen, Ronald 0 0
Calhoun, Christopher 1,001,940 4,592,750
Hedrick, Marc 295,630 1,287,564
Saad, Mark 260,000 1,156,800
Shirahama, Seijiro 0 0
Reuter, Bruce 260,000 876,250
Arm, Douglas 0 0
Milstein, Alexander 0 0
Kleinhenz, Kenneth 0 0
Rickey, David 0 0
Holmes, E. Carmack 0 0
Hawran, Paul 0 0
Hawkins, Richard 0 0

Insider Trading

» Full list on Insider Trading
view people for: